Traws Pharma Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Traws Pharma hat ein Gesamteigenkapital von $1.7M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $11.5M bzw. $9.8M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

US$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$5.02m
Eigenkapital	US$1.69m
Gesamtverbindlichkeiten	US$9.78m
Gesamtvermögen	US$11.47m

Jüngste Berichte zur Finanzlage

Recent updates

Narrative-Update • Jun 26

TRAW: Influenza Setback Will Shift Focus Toward Broad Antiviral Pipeline Potential

Analysts cut their price target on Traws Pharma stock to $1 from $8, reflecting reduced confidence in the near term after the deferral of the tivoxavir marboxil Phase 2a influenza challenge study and what they describe as lower visibility on the company's next potential value driver. What’s in the News for Traws Pharma Traws Pharma is preparing an updated toxicology data package for tivoxavir marboxil to address information requests from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency, with resubmission planned in the third quarter of 2026.

Neues Narrative • Apr 30

Pandemic Preparedness And Once Monthly Oral Flu Prophylaxis Will Transform This Antiviral Opportunity

Catalysts About Traws Pharma Traws Pharma is a biotechnology company focused on developing next generation antiviral treatments and prophylactic agents for influenza. What are the underlying business or industry changes driving this perspective?

Neues Narrative • Apr 16

Regulatory And Funding Risks Around Influenza Catalyst Will Eventually Support A Healthier Outlook

Catalysts About Traws Pharma Traws Pharma is a clinical stage company focused on developing next generation antiviral treatments and prophylactic therapies for influenza. What are the underlying business or industry changes driving this perspective?

Analyseartikel • Mar 09

We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyseartikel • Apr 22

Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analyseartikel • Jul 27

Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analyseartikel • Mar 21

Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analyseartikel • Dec 06

Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: TRAWDie kurzfristigen Aktiva des Unternehmens ($9.0M) decken seine kurzfristigen Passiva ($9.7M) nicht.

Langfristige Verbindlichkeiten: TRAWDie kurzfristigen Vermögenswerte des Unternehmens ($9.0M) übersteigen seine langfristigen Verbindlichkeiten ($44.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: TRAW ist schuldenfrei.

Schulden abbauen: TRAW hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: TRAW hat auf der Grundlage seines derzeitigen freier Cashflows weniger als ein Jahr Liquiditätsspielraum.

Vorhersage Cash Runway: TRAW hat weniger als ein Jahr Liquiditätsreserven, wenn der freie Cashflow weiterhin mit den historischen Raten von 2.9% pro Jahr abnimmt

Entdecken Sie finanziell stabile Unternehmen

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/08/16 03:16
Aktienkurs zum Tagesende	2026/08/14 00:00
Gewinne	2026/06/30
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Traws Pharma, Inc. wird von 10 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Kimberly Lee	Brean Capital Historical (Janney Montgomery)
Michael Thomas Cooper	Edison Investment Research
Etzer Darout	Guggenheim Securities, LLC

Traws Pharma Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Traws Pharma, Inc. announced delayed annual 10-K filing

Traws Pharma Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

Traws Pharma Receives Non-Compliance Letter from Nasdaq Regarding Non-Compliance with the Minimum $2.5 Million Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1)

Nasdaq Determines to Delist Traws Pharma's Securities

Traws Pharma Receives Letter from The Nasdaq Capital Market Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Traws Pharma, Inc. announced delayed 10-Q filing

Recent updates

TRAW: Influenza Setback Will Shift Focus Toward Broad Antiviral Pipeline Potential

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

Traws Pharma Provides Regulatory Update on Influenza Program

Traws Pharma, Inc., Annual General Meeting, Jul 08, 2026

Pandemic Preparedness And Once Monthly Oral Flu Prophylaxis Will Transform This Antiviral Opportunity

Traws Pharma, Inc. announced that it expects to receive $10 million in funding from Sirenia Capital Management LP

Regulatory And Funding Risks Around Influenza Catalyst Will Eventually Support A Healthier Outlook

Traws Pharma, Inc. announced delayed annual 10-K filing

Traws Pharma, Inc. Completes Analysis of Ratutrelvir Clinical Study in Paxlovid-Eligible and Ineligible Covid-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as A Prophylactic Treatment for Seasonal Influenza

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in Paxlovid-19 Patients

Traws Pharma, Inc. Reports Positive Interim Clinical Data with Ratutrelvir Versus Paxlovid™?, Shows Activity in Paxlovid-Ineligible COVID-19 Patients

Expert Systems Inc. Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Traws Pharma, Inc., Annual General Meeting, Nov 21, 2025

Traws Pharma, Inc. Appoints John Leaman to Its Board of Directors as an Independent Director, Effective October 1, 2025

Traws Pharma, Inc. Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Traws Pharma, Inc. to Report Q2, 2025 Results on Aug 14, 2025

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Traws Pharma, Inc. Announces CEO Changes

Traws Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $5.5142 million.

Traws Pharma Reports Positive Results from an Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Traws Pharma Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

Traws Pharma Inc. Announces CFO Changes

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Traws Pharma, Inc. announced that it expects to receive $72.6 million in funding

Traws Pharma, Inc. Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Receives Non-Compliance Letter from Nasdaq Regarding Non-Compliance with the Minimum $2.5 Million Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1)

Traws Pharma, Inc., Annual General Meeting, Oct 31, 2024

Traws Pharma, Inc. Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Traws Pharma, Inc. Announces Positive Topline Phase 1 Results for Covid Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Nasdaq Determines to Delist Traws Pharma's Securities

Traws Pharma, Inc. Announces Board Changes

Traws Pharma Receives Letter from The Nasdaq Capital Market Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Traws Pharma, Inc. announced delayed 10-Q filing

Traws Pharma, Inc. to Report Q2, 2024 Results on Aug 15, 2024

Price target decreased by 22% to US$6.50

New minor risk - Shareholder dilution

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy

High number of new directors

Consensus revenue estimates decrease by 19%, EPS upgraded

Traws Pharma, Inc. Announces Chief Executive Office Changes

Traws Pharma, Inc. Announces Board Changes

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc

We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate

Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

Consensus EPS estimates upgraded to US$0.97 loss

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Onconova Therapeutics, Inc. Appoints Victor Moyo as Chief Medical Officer

Onconova Therapeutics Receives A Letter from the Nasdaq Capital Market Regarding Minimum Bid Price Requirement

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Onconova Therapeutics, Inc. Presents Preclinical Data on Narazaciclib at the 17Th International Conference on Malignant Lymphoma

Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2023

Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Onconova Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation

Consensus revenue estimates fall by 13%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Onconova Therapeutics, Inc. Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Insufficient new directors